Family medicine clinicians prescribing GLP-1 agents must account for the reality that roughly one in three obesity patients discontinues or transitions out of retail pharmacy channels, a discontinuation pattern that directly undermines the chronic, sustained treatment these medications require for meaningful weight and cardiometabolic outcomes. The differential persistence between diabetes and obesity indications, approximately 5.5 percentage points, likely reflects differences in insurance coverage stability, out-of-pocket cost burden, and patient-perceived urgency, all of which fall within the counseling and care coordination scope of the primary care visit. Monitoring persistence and proactively addressing access barriers at follow-up appointments is therefore a clinically actionable responsibility for the family medicine physician managing these patients longitudinally.
Based on the available abstract data from the AMCP Annual 2026 presentation, this analysis examined real-world utilization and persistence patterns among patients prescribed GLP-1 receptor agonists across two primary indications: type 2 diabetes and obesity. The data captured channel-level retention, distinguishing between retail pharmacy access and other distribution pathways, to characterize how patients engage with these therapies over time in a non-clinical, commercial setting.
The key finding centers on differential persistence rates between the two patient populations. Approximately 72% of patients using GLP-1 agents for diabetes management remained in retail pharmacy channels, compared to roughly 66.5% of those prescribed these medications for obesity. This gap suggests that patients initiating GLP-1 therapy for glycemic control demonstrate modestly stronger channel retention than those using the same drug class for weight management. Approximately 28% of the broader cohort did not sustain engagement through retail channels, reflecting a meaningful proportion of patients who may be discontinuing, switching to alternative dispensing pathways, or facing access barriers.
For prescribers, these persistence figures carry direct clinical implications. Suboptimal continuation of GLP-1 therapy, whether for metabolic or weight-related indications, undermines the cumulative cardiometabolic and anthropometric benefits that require sustained exposure to manifest. The lower retention observed in the obesity cohort may reflect differences in insurance coverage, out-of-pocket costs, patient expectations around weight loss trajectory, or tolerability profiles in individuals without a diabetes diagnosis. Clinicians managing patients on GLP-1 agents for either indication should proactively assess adherence at each encounter and address structural and patient-level factors that contribute to early discontinuation before therapeutic goals are achieved.
GLP-1 receptor agonists are increasingly central to managing both type 2 diabetes and obesity, but real-world persistence data reveal a meaningful gap between clinical potential and long-term patient adherence. Approximately 72% of patients using GLP-1 agents for diabetes remained in retail pharmacy channels, compared to roughly 66.5% for those using them for obesity, with around 28% discontinuing therapy. These figures highlight that a substantial portion of patients are not staying on treatment long enough to realize the full metabolic benefits. In family medicine practice, proactively scheduling follow-up visits at the 90-day mark can help identify patients at highest risk of discontinuation and allow clinicians to address barriers such as cost, side effects, or unmet expectations before therapy lapses.
“The persistence gap between diabetes and obesity GLP-1 users is one of the most clinically important numbers in this space right now, and 66.5% retention for obesity indications should be a wake-up call for every prescriber. When I sit down with a patient starting semaglutide or tirzepatide for weight management, I now make a point of explicitly addressing that dropout risk on day one, framing the conversation around long-term metabolic investment rather than a short-term intervention. The data tell us that the drug works, but the patient relationship and expectation-setting are what determine whether they stay on it long enough to see meaningful outcomes. Proactive check-ins at the 30- and 90-day marks are no longer optional in my practice, they are a structural part of the protocol.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What are GLP-1 drugs and what conditions are they used to treat?
- Why do some patients stop taking GLP-1 medications after starting them?
- Are GLP-1 medications more commonly used for diabetes or obesity right now?
- What does it mean that GLP-1 medications are obtained through retail channels?
- Will GLP-1 drugs continue to grow in use over the coming years?
- Is there a difference in how well patients stick with GLP-1 therapy for diabetes versus obesity?
- What happens if a patient stops a GLP-1 medication before reaching their health goals?
- Are GLP-1 medications covered by insurance for obesity treatment?
- What role do managed care organizations play in patients’ access to GLP-1 therapy?
- Are GLP-1 medications safe to take long-term?
FAQ
What are GLP-1 drugs and what conditions are they used to treat?
GLP-1 drugs are a class of medications that mimic a natural hormone called glucagon-like peptide-1, which helps regulate blood sugar and appetite. They are currently approved and widely used for the treatment of type 2 diabetes and obesity. Their use is expanding as research continues to show benefits across multiple metabolic conditions.
Why do some patients stop taking GLP-1 medications after starting them?
Persistence, meaning staying on a medication long-term, is one of the biggest challenges with GLP-1 therapy. Data show that roughly 28% of patients discontinue these medications, with obesity patients showing slightly lower persistence rates than diabetes patients. Side effects, cost, and access issues are among the most common reasons patients stop treatment.
Are GLP-1 medications more commonly used for diabetes or obesity right now?
Both conditions represent major areas of use, though historically GLP-1 medications were prescribed primarily for type 2 diabetes. The obesity indication has grown substantially in recent years as newer formulations have received approval specifically for weight management. Research presented at major pharmacy and managed care meetings continues to highlight the growth of both indications.
What does it mean that GLP-1 medications are obtained through retail channels?
Retail channels refer to traditional pharmacies where patients fill prescriptions in person or through mail-order services connected to those pharmacy networks. About 72% of diabetes patients using GLP-1 drugs obtain them this way. This distribution pattern matters for tracking access, adherence, and cost trends across large patient populations.
Will GLP-1 drugs continue to grow in use over the coming years?
Current evidence and market projections strongly support continued growth in GLP-1 prescribing for both obesity and diabetes. New formulations, additional approved indications, and growing clinical evidence of cardiovascular and kidney benefits are driving expanded use. Managed care organizations and payers are closely monitoring this growth because of its significant cost implications.
Is there a difference in how well patients stick with GLP-1 therapy for diabetes versus obesity?
Yes, persistence rates differ modestly between the two conditions. Approximately 72% of diabetes patients remain on GLP-1 therapy through retail channels, compared to roughly 66.5% for those using these medications for obesity. This gap may reflect differences in insurance coverage, perceived urgency of treatment, or the experience of side effects.
What happens if a patient stops a GLP-1 medication before reaching their health goals?
Discontinuing GLP-1 therapy before achieving target outcomes often leads to weight regain or worsening blood sugar control. These medications manage chronic conditions that typically require long-term treatment rather than a fixed course. Patients should discuss any concerns about side effects or cost with their provider before stopping, as adjustments to dosing or formulation may help.
Are GLP-1 medications covered by insurance for obesity treatment?
Coverage for GLP-1 medications in obesity varies widely depending on the insurance plan, employer, or government program. Diabetes indications tend to have broader coverage than obesity indications, which has contributed to the persistence gap between the two uses. Patients should work with their provider and pharmacist to explore prior authorization, patient assistance programs, and alternative coverage options.
What role do managed care organizations play in patients’ access to GLP-1 therapy?
Managed care organizations, including health insurance plans and pharmacy benefit managers, determine formulary placement, prior authorization requirements, and cost-sharing structures for GLP-1 medications. Their decisions directly affect whether patients can afford and consistently access these treatments. As utilization grows, these organizations are increasingly focused on balancing clinical benefit with cost management strategies.
Are GLP-1 medications safe to take long-term?
The long-term safety profile of GLP-1 medications has been studied extensively in large clinical trials, and they are generally considered safe for ongoing use in appropriate patients. Common side effects such as nausea and gastrointestinal discomfort often improve over time with proper dose titration. Regular follow-up with a physician is important to monitor for any individual concerns and to ensure the treatment plan remains appropriate.
